GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Common Stock

CAMP (Camp4 Therapeutics) Common Stock : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Common Stock?

Camp4 Therapeutics's quarterly common stock increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then stayed the same from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Camp4 Therapeutics's annual common stock stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).


Camp4 Therapeutics Common Stock Historical Data

The historical data trend for Camp4 Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics Common Stock Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Common Stock
- - -

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial - - - - -

Camp4 Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Camp4 Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.